Other Clinical Trial - A Study of BL-B01D1+PD-1 Monoclonal Antibody in

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04985851` - To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.	N/A
Completed	`NCT01987232` - Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT06427369` - An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer	Phase 1
Recruiting	`NCT06223711` - Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC	Phase 2
Completed	`NCT05002868` - Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors	Phase 1
Recruiting	`NCT04790253` - PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)	N/A
Withdrawn	`NCT05572476` - Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer	Phase 2
Recruiting	`NCT05874401` - Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan	Phase 4
Not yet recruiting	`NCT06008353` - A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil
Recruiting	`NCT04947774` - Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer
Completed	`NCT04902885` - Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or Topotecan	Phase 3
Active, not recruiting	`NCT05280470` - Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)	Phase 2
Recruiting	`NCT05765825` - Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC	Phase 2
Recruiting	`NCT05761977` - Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer
Active, not recruiting	`NCT05092412` - Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC	Phase 2
Not yet recruiting	`NCT06306560` - A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.	Phase 2
Recruiting	`NCT06211036` - Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab	Phase 3
Recruiting	`NCT04894591` - To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
Not yet recruiting	`NCT06449209` - Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy	Phase 2
Completed	`NCT04878016` - A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC	Phase 3

NCT number	NCT06437509
Study type	Interventional
Source	Sichuan Baili Pharmaceutical Co., Ltd.
Contact	Sa Xiao, PHD
Phone	15013238943
Email	xiaosa@baili-pharm.com
Status	Not yet recruiting
Phase	Phase 2
Start date	June 2024
Completion date	June 2026

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms